TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9727211

Group type: EXPERIMENTAL
Intervention: Harbinger (PACT model)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 8408456

Group type: EXPERIMENTAL
Intervention: 200 micrograms iodine/day from weeks 17-18 of pregnancy until 12 months after delivery
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no iodine supplementation)
Number of subjects: 54
Study: 2936636

Group type: EXPERIMENTAL
Intervention: Combination of 2% miconazole nitrate and 5% benzoyl peroxide applied twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical application of 1% isoconazole nitrate in the morning followed in the evening by 5% benzoyl peroxide
Number of subjects: 0
Study: 29498033

Group type: EXPERIMENTAL
Intervention: Terrorism-related pictures
Number of subjects: 95

Group type: COMPARATOR
Intervention: Neutral pictures
Number of subjects: 95
Study: 25824852

Group type: EXPERIMENTAL
Intervention: Community treatment by experts (CTBE)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 71
Study: 25527244

Group type: EXPERIMENTAL
Intervention: IF-BMOS
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: IF-BMOS + Pro
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control
Number of subjects: 189
Study: 21719490

Group type: EXPERIMENTAL
Intervention: Home respiratory polygraphy (RP) and home follow‐up
Number of subjects: 66

Group type: COMPARATOR
Intervention: Hospital polysomnography and hospital follow‐up
Number of subjects: 66

Group type: COMPARATOR
Intervention: Home RP and hospital follow‐up
Number of subjects: 66
Study: 20384968

Group type: EXPERIMENTAL
Intervention: OROS(®) hydromorphone
Number of subjects: 504

Group type: COMPARATOR
Intervention: SR oxycodone
Number of subjects: 504
Study: 18534364

Group type: EXPERIMENTAL
Intervention: Medically treated patients with prolonged QRS duration (QRSd ≥140 ms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ICD-treated patients with prolonged QRS duration (QRSd ≥140 ms)
Number of subjects: 0
Study: 16355614

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: MI plus Captopril
Number of subjects: 69

Group type: COMPARATOR
Intervention: MI
Number of subjects: 69
Study: 12622301

Group type: EXPERIMENTAL
Intervention: Beating the Blues (BtB)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 167
Study: 11374327

Group type: EXPERIMENTAL
Intervention: 30 mg oxazepam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9604193

Group type: EXPERIMENTAL
Intervention: ACL reconstruction
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (contralateral asymptomatic knees)
Number of subjects: 44
Study: 7948794

Group type: EXPERIMENTAL
Intervention: Rultract retractor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pittman retractor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Cooley retractor, no IMA harvest)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall IMA retractor groups (Rultract and Pittman)
Number of subjects: 0
Study: 3590300

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (PP)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Cold storage (CS)
Number of subjects: 107
Study: 30768793

Group type: EXPERIMENTAL
Intervention: Supportive-expressive therapy for MDD; details on dosage and duration not available.
Number of subjects: 1
Study: 28332010

Group type: EXPERIMENTAL
Intervention: Supervised walking program
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Unsupervised walking program
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Adherent participants with preference
Number of subjects: 69
Study: 26793643

Group type: EXPERIMENTAL
Intervention: Educational pamphlet sent to intervention group after randomization.
Number of subjects: 200
Study: 24293756

Group type: EXPERIMENTAL
Intervention: Vestipitant (15 mg)
Number of subjects: 161
Study: 21303515

Group type: EXPERIMENTAL
Intervention: Hand-suture
Number of subjects: 334

Group type: COMPARATOR
Intervention: Stapling
Number of subjects: 334
Study: 19467175

Group type: EXPERIMENTAL
Intervention: Mometasone furoate, 200 mcg once daily
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 17009541

Group type: EXPERIMENTAL
Intervention: Oral Chinese medicine with massage
Number of subjects: 72

Group type: COMPARATOR
Intervention: Oral Chinese medicine only
Number of subjects: 72
Study: 15297084

Group type: EXPERIMENTAL
Intervention: n-3 PUFAs
Number of subjects: 300

Group type: COMPARATOR
Intervention: corn oil
Number of subjects: 300
Study: 10647548

Group type: EXPERIMENTAL
Intervention: Isometric resistance training for 8 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (untrained leg)
Number of subjects: 10
Study: 9066384

Group type: EXPERIMENTAL
Intervention: Intermittent warm blood cardioplegia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cold blood cardioplegia
Number of subjects: 40
Study: 8374913

Group type: EXPERIMENTAL
Intervention: Selegiline (deprenyl)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lazabemide (Ro 19‐6327)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of Selegiline and Lazabemide
Number of subjects: 20
Study: 31623545

Group type: EXPERIMENTAL
Intervention: Gait Enhancing and Motivating System (GEMS) during gait training
Number of subjects: 26

Group type: COMPARATOR
Intervention: Gait training without Gait Enhancing and Motivating System
Number of subjects: 26
Study: 28403910

Group type: EXPERIMENTAL
Intervention: Jaungo applied twice a day for 3 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Jaungo and placebo ointment applied once a day for 3 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo ointment applied twice a day for 3 weeks
Number of subjects: 34
Study: 25514459

Group type: EXPERIMENTAL
Intervention: 0.3 ppm ozone at 22°C
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.3 ppm ozone at 32.5°C
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ozone exposure at both temperatures
Number of subjects: 16
Study: 23307204

Group type: EXPERIMENTAL
Intervention: AdenoPlus
Number of subjects: 128

Group type: COMPARATOR
Intervention: CC‐IFA
Number of subjects: 128
Study: 22070744

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (cumulative dose 72.5 mg/kg)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 400
Study: 18469252

Group type: EXPERIMENTAL
Intervention: High dietary total antioxidant capacity (HT) diet
Number of subjects: 33

Group type: COMPARATOR
Intervention: Low dietary total antioxidant capacity (LT) diet
Number of subjects: 33
Study: 16948743

Group type: EXPERIMENTAL
Intervention: Individually optimized postventricular atrial blanking period (PVAB)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Standard programming of the PVAB (nominal of 100 msec)
Number of subjects: 207
Study: 12940868

Group type: EXPERIMENTAL
Intervention: Mix50/Mix25 (Mix50 before breakfast and Mix25 before evening meal)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Mix25 twice daily (Mix25 before both breakfast and evening meal)
Number of subjects: 116
Study: 11130522

Group type: EXPERIMENTAL
Intervention: Calcium antagonists (n=12,699)
Number of subjects: 27743

Group type: COMPARATOR
Intervention: Other antihypertensive drugs (n=15,044)
Number of subjects: 27743
Study: 9182738

Group type: COMPARATOR
Intervention: HAND (hand curets)
Number of subjects: 15

Group type: COMPARATOR
Intervention: US (standard smooth ultrasonic tip)
Number of subjects: 15

Group type: COMPARATOR
Intervention: FINDIAM (fine grit diamond-coated ultrasonic tips)
Number of subjects: 15

Group type: COMPARATOR
Intervention: MEDDIAM (medium grit diamond-coated ultrasonic tips)
Number of subjects: 15
Study: 1359629

Group type: EXPERIMENTAL
Intervention: olsalazine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pentasa
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All drugs
Number of subjects: 20
Study: 3704609

Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactulose (Duphalac)
Number of subjects: 0
Study: 30507227

Group type: EXPERIMENTAL
Intervention: Cognitive bias modification for interpretation (CBM-I) with RNT priming
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Cognitive bias modification for interpretation (CBM-I) without RNT priming
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control condition (no CBM-I)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: CBM-I training (across diagnostic groups)
Number of subjects: 131
Study: 27430652

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 1150
Study: 24123134

Group type: EXPERIMENTAL
Intervention: Vitamin D3 at 200 IU/day (low dose)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Vitamin D3 at 2000 IU/day (high dose)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study: 22045128

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg at the orbicularis oris muscle
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg at the corrugator supercilii muscle
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg at the adductor pollicis muscle
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg at the orbicularis oris and corrugator supercilii muscles
Number of subjects: 54
Study: 20946739

Group type: EXPERIMENTAL
Intervention: Contact with community agencies
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Going to Alcoholics Anonymous (AA)
Number of subjects: 672

Group type: COMPARATOR
Intervention: Heavy-drinking network
Number of subjects: 672

Group type: COMPARATOR
Intervention: Receiving suggestions to do something about one's drinking
Number of subjects: 672

Group type: COMPARATOR
Intervention: Going to treatment
Number of subjects: 672
Study: 17429677

Group type: EXPERIMENTAL
Intervention: 20‐s Wingate anaerobic test (20‐WAT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 30‐s Wingate anaerobic test (30‐WAT)
Number of subjects: 50
Study: 15297081

Group type: EXPERIMENTAL
Intervention: Synbiotic preparation (Lactobacillus acidophilus La5, Bifidobacterium lactis Bb 12, Streptococcus thermophilus, Lactobacillus bulgaricus with oligofructose)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Synbiotic preparation
Number of subjects: 90
Study: 11720813

Group type: EXPERIMENTAL
Intervention: LKM512 yogurt
Number of subjects: 0
Study: 9399419

Group type: EXPERIMENTAL
Intervention: Methacholine stimulation test
Number of subjects: 42

Group type: COMPARATOR
Intervention: Screening spirometry
Number of subjects: 42
Study: 7959544

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients
Number of subjects: 47

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 47
Study: 3301154

Group type: EXPERIMENTAL
Intervention: Intramuscular dezocine (10 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Butorphanol (2 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30471138

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine with nevirapine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Nevirapine without artemether-lumefantrine
Number of subjects: 150
Study: 27624173

Group type: EXPERIMENTAL
Intervention: 1.25 mg Bevacizumab plus 300 µg/0.1 mL Diclofenac (IVB/D)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 1.25 mg intravitreal Bevacizumab (IVB)
Number of subjects: 80
Study: 27297370

Group type: EXPERIMENTAL
Intervention: Child‐ and Parent‐focused Violence Intervention Program (experimental group)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Routine psychiatric care (control group)
Number of subjects: 69
Study: 25445103

Group type: EXPERIMENTAL
Intervention: 3 ml of EMLA (lidocaine-prilocaine cream)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 3 ml of placebo
Number of subjects: 100
Study: 22044111

Group type: EXPERIMENTAL
Intervention: GT/Profile protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RaCe/NiTi protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: N/A (comparison of techniques)
Number of subjects: 0
Study: 19225139

Group type: EXPERIMENTAL
Intervention: Folate and betaine treatment
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 17890873

Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD) patients
Number of subjects: 249

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 249
Study: 16212799

Group type: EXPERIMENTAL
Intervention: albendazole
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: mebendazole
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: albendazole and mebendazole (combined results)
Number of subjects: 122
Study: 11979067

Group type: EXPERIMENTAL
Intervention: 2 mg of nicotine polacrilex
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Tacrine treatment
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Single-dose nicotine
Number of subjects: 13
Study: 10396215

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 10
Study: 7594291

Group type: EXPERIMENTAL
Intervention: Steroid injection with lidocaine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo injection with lidocaine
Number of subjects: 24
Study: 2329813

Group type: EXPERIMENTAL
Intervention: Single dose of total triterpenic fraction of Centella asiatica (30 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single dose of total triterpenic fraction of Centella asiatica (60 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chronic treatment with total triterpenic fraction of Centella asiatica (30 mg twice daily for 7 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chronic treatment with total triterpenic fraction of Centella asiatica (60 mg twice daily for 7 days)
Number of subjects: 12
Study: 6990745

Group type: EXPERIMENTAL
Intervention: Inhalation isoetharine hydrochloride
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline sulfate
Number of subjects: 269
Study: 31276265

Group type: EXPERIMENTAL
Intervention: 0.1% mometasone furoate (MF) cream + LA‐Cer‐containing moisturizer
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.1% mometasone furoate (MF) cream
Number of subjects: 0
Study: 28142364

Group type: EXPERIMENTAL
Intervention: Enhanced Transtheoretical Model Intervention (ETMI)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual physical therapy (Control)
Number of subjects: 220
Study: 26278876

Group type: EXPERIMENTAL
Intervention: Proposed Nutrition Facts label
Number of subjects: 273

Group type: COMPARATOR
Intervention: Current Nutrition Facts label
Number of subjects: 273
Study: 23472458

Group type: EXPERIMENTAL
Intervention: Virgin Argan Oil (VAO) for 3 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil (EVO) for 3 weeks
Number of subjects: 60
Study: 21208922

Group type: EXPERIMENTAL
Intervention: 2 doses of varicella vaccine
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: 1 dose of varicella vaccine
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: No varicella vaccine
Number of subjects: 211
Study: 19948038

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AL)
Number of subjects: 246

Group type: COMPARATOR
Intervention: dihydroartemisinin-piperaquine (DP)
Number of subjects: 246
Study: 17267326

Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg/day
Number of subjects: 206

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/day
Number of subjects: 206
Study: 15310086

Group type: EXPERIMENTAL
Intervention: Megamin (3.6 g daily for 6 to 8 weeks)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Lycopenomin (1.2 g daily for 6 to 8 weeks)
Number of subjects: 61
Study: 12520630

Group type: EXPERIMENTAL
Intervention: ReN1869 (3.5 to 95 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: ReN1869
Number of subjects: 56
Study: 9686500

Group type: EXPERIMENTAL
Intervention: Serum concentration of PIIINP in MPD patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Primary osteomyelofibrosis patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: MPD patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Serum concentration of PIIINP
Number of subjects: 48
Study: 7928669

Group type: EXPERIMENTAL
Intervention: Vapor only (V) freezing method
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Vapor for 12 minutes followed by submersion into liquid nitrogen (V+N2) freezing method
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Direct submersion into liquid nitrogen (N2) freezing method
Number of subjects: 19

Group type: COMPARATOR
Intervention: Fresh samples
Number of subjects: 19
Study: 2528841

Group type: EXPERIMENTAL
Intervention: Ketanserin (20 mg t.i.d. for 1 month, 40 mg t.i.d. thereafter; n = 63 patients)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo (n = 84 patients)
Number of subjects: 173
Study: 756476

Group type: EXPERIMENTAL
Intervention: Brief psychotherapy and behavior therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 27
Study: 30945994

Group type: EXPERIMENTAL
Intervention: Valgus knee brace and lateral wedge insole (combined)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Valgus knee brace (isolation)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Lateral wedge insole (isolation)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combined usage of both interventions
Number of subjects: 21
Study: 30395189

Group type: EXPERIMENTAL
Intervention: BiXGBoost
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random forest-based methods
Number of subjects: 0
Study: 28851088

Group type: EXPERIMENTAL
Intervention: ALA-DAG (2.5 g/d for 12 weeks)
Number of subjects: 114

Group type: COMPARATOR
Intervention: ALA-TAG (2.5 g/d for 12 weeks)
Number of subjects: 114
Study: 23837534

Group type: EXPERIMENTAL
Intervention: Development plan intended to enhance user participation implemented in the intervention hospital.
Number of subjects: 1651

Group type: COMPARATOR
Intervention: Control hospitals (no specific intervention mentioned).
Number of subjects: 1651
Study: 21450580

Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous training (MIT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study: 20615317

Group type: EXPERIMENTAL
Intervention: Rush build-up schedule with Depigoid-SCIT (0.2 mL on day 1, 0.3 mL on day 1, 0.5 mL on day 28)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Conventional 4-week build-up schedule
Number of subjects: 303
Study: 18488201

Group type: EXPERIMENTAL
Intervention: S‐ketamine (NMDA antagonist)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: DMT (5HT2A agonist)
Number of subjects: 15
Study: 16170235

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (6 mg/70 kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Triazolam (1 and 2 mg/70 kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 12574201

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10573698

Group type: EXPERIMENTAL
Intervention: PCR diagnosis using IS6110 amplification
Number of subjects: 143
Study: 8542104

Group type: EXPERIMENTAL
Intervention: Azelastine 6 mg twice per day
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 1922236

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with cyclophosphamide, methotrexate, and fluorouracil
Number of subjects: 250

Group type: COMPARATOR
Intervention: Observation (no further treatment) followed by reinduction therapy with cyclophosphamide, methotrexate, and fluorouracil
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Reinduction therapy with cyclophosphamide, methotrexate, and fluorouracil
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Overall survival for maintenance therapy group
Number of subjects: 250

Group type: COMPARATOR
Intervention: Overall survival for observation group
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Overall survival for all patients
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 250
Study: 6405607

Group type: EXPERIMENTAL
Intervention: Copper supplement (80 micrograms/kg/day as sulphate)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 31651324

Group type: EXPERIMENTAL
Intervention: Pirfenidone treatment
Number of subjects: 277
Study: 30488504

Group type: EXPERIMENTAL
Intervention: Albumin‐polyaldehyde sealant applied to pharyngeal repair
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no sealant)
Number of subjects: 45
Study: 27113884

Group type: EXPERIMENTAL
Intervention: Riboflavin‐dextran
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Hypotonic riboflavin
Number of subjects: 48
Study: 25440482

Group type: COMPARATOR
Intervention: UHC
Number of subjects: 56197

Group type: EXPERIMENTAL
Intervention: NSQIP
Number of subjects: 56197
Study: 21982106

Group type: EXPERIMENTAL
Intervention: Subconjunctival bevacizumab (2.5 mg/0.1 mL)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Mitomycin C (0.02% for 3 minutes)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Comparison of IOP between groups
Number of subjects: 36
Study: 19557167

Group type: EXPERIMENTAL
Intervention: Abrupt weaning at 4 months
Number of subjects: 958

Group type: COMPARATOR
Intervention: Continued breastfeeding
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: Abrupt weaning at 4 months (mothers with less severe disease)
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: Abrupt weaning at 4 months (mothers with more severe disease)
Number of subjects: 958

Group type: COMPARATOR
Intervention: Weaning before 15 months (control group)
Number of subjects: 958
Study: 17956917

Group type: EXPERIMENTAL
Intervention: Intensive exercise training (IET) for 3 weeks after hospital discharge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study: 16891588

Group type: EXPERIMENTAL
Intervention: 17-mg hydrocortisone
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27